Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

BACKGROUND. Vemurafenib has been approved for the treatment of patients with advanced BRAF(V600E)-mutant melanoma. This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs) that occur in vemurafenib-treated patients, including cutaneou...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Lacouture, Mario E., Duvic, Madeleine, Hauschild, Axel, Prieto, Victor G., Robert, Caroline, Schadendorf, Dirk, Kim, Caroline C., McCormack, Christopher J., Myskowski, Patricia L., Spleiss, Olivia, Trunzer, Kerstin, Su, Fei, Nelson, Betty, Nolop, Keith B., Grippo, Joseph F., Lee, Richard J., Klimek, Matthew J., Troy, James L., Joe, Andrew K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2013
Pynciau:
Melanoma and Cutaneous Malignancies
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607529/
https://ncbi.nlm.nih.gov/pubmed/23457002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0333
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg